Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
<p><strong>Objective:</strong> To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England.</p> <p><strong>Design:</strong> Retrosp...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ
2023
|
| _version_ | 1826311729472077824 |
|---|---|
| author | Green, ACA Curtis, HJ Higgins, R Nab, L Mahalingasivam, V Smith, RM Mehrkar, A Inglesby, P Drysdale, H DeVito, NJ Croker, R Rentsch, CT Bhaskaran, K Tazare, J Zheng, B Andrews, CD Bacon, SCJ Davy, S Dillingham, I Evans, D Fisher, L Hickman, G Hopcroft, LEM Hulme, WJ Massey, J MacDonald, O Morley, J Morton, CE Park, RY Walker, AJ Ward, T Wiedemann, M Bates, C Cockburn, J Parry, J Hester, F Harper, S Douglas, IJ Evans, SJW Goldacre, B Tomlinson, LA MacKenna, B |
| author_facet | Green, ACA Curtis, HJ Higgins, R Nab, L Mahalingasivam, V Smith, RM Mehrkar, A Inglesby, P Drysdale, H DeVito, NJ Croker, R Rentsch, CT Bhaskaran, K Tazare, J Zheng, B Andrews, CD Bacon, SCJ Davy, S Dillingham, I Evans, D Fisher, L Hickman, G Hopcroft, LEM Hulme, WJ Massey, J MacDonald, O Morley, J Morton, CE Park, RY Walker, AJ Ward, T Wiedemann, M Bates, C Cockburn, J Parry, J Hester, F Harper, S Douglas, IJ Evans, SJW Goldacre, B Tomlinson, LA MacKenna, B |
| author_sort | Green, ACA |
| collection | OXFORD |
| description | <p><strong>Objective:</strong> To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England.</p>
<p><strong>Design:</strong> Retrospective, descriptive cohort study, approved by NHS England.</p>
<p><strong>Setting:</strong> Routine clinical data from 23.4 million people linked to data on covid-19 infection and treatment, within the OpenSAFELY-TPP database.</p>
<p><strong>Participants:</strong> Outpatients with covid-19 at high risk of severe outcomes.</p>
<p><strong>Interventions:</strong> Nirmatrelvir/ritonavir (paxlovid), sotrovimab, molnupiravir, casirivimab/imdevimab, or remdesivir, used in the community by covid-19 medicine delivery units.</p>
<p><strong>Results:</strong> 93 870 outpatients with covid-19 were identified between 11 December 2021 and 28 April 2022 to be at high risk of severe outcomes and therefore potentially eligible for antiviral or nMAB treatment (or both). Of these patients, 19 040 (20%) received treatment (sotrovimab, 9660 (51%); molnupiravir, 4620 (24%); paxlovid, 4680 (25%); casirivimab/imdevimab, 50 (<1%); and remdesivir, 30 (<1%)). The proportion of patients treated increased from 9% (190/2220) in the first week of treatment availability to 29% (460/1600) in the latest week. The proportion treated varied by high risk group, being lowest in those with liver disease (16%; 95% confidence interval 15% to 17%); by treatment type, with sotrovimab favoured over molnupiravir and paxlovid in all but three high risk groups (Down's syndrome (35%; 30% to 39%), rare neurological conditions (45%; 43% to 47%), and immune deficiencies (48%; 47% to 50%)); by age, ranging from ≥80 years (13%; 12% to 14%) to 50-59 years (23%; 22% to 23%); by ethnic group, ranging from black (11%; 10% to 12%) to white (21%; 21% to 21%); by NHS region, ranging from 13% (12% to 14%) in Yorkshire and the Humber to 25% (24% to 25%) in the East of England); and by deprivation level, ranging from 15% (14% to 15%) in the most deprived areas to 23% (23% to 24%) in the least deprived areas. Groups that also had lower coverage included unvaccinated patients (7%; 6% to 9%), those with dementia (6%; 5% to 7%), and care home residents (6%; 6% to 7%).</p>
<p><strong>Conclusions:</strong> Using the OpenSAFELY platform, we were able to identify patients with covid-19 at high risk of severe outcomes who were potentially eligible to receive treatment and assess the coverage of these new treatments among these patients. In the context of a rapid deployment of a new service, the NHS analytical code used to determine eligibility could have been over-inclusive and some of the eligibility criteria not fully captured in healthcare data. However targeted activity might be needed to resolve apparent lower treatment coverage observed among certain groups, in particular (at present): different NHS regions, ethnic groups, people aged ≥80 years, those living in socioeconomically deprived areas, and care home residents.</p> |
| first_indexed | 2024-03-07T08:14:02Z |
| format | Journal article |
| id | oxford-uuid:5ea26d80-47f1-4963-91da-e3db8fd43e80 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:14:02Z |
| publishDate | 2023 |
| publisher | BMJ |
| record_format | dspace |
| spelling | oxford-uuid:5ea26d80-47f1-4963-91da-e3db8fd43e802023-12-18T15:17:33ZTrends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELYJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5ea26d80-47f1-4963-91da-e3db8fd43e80EnglishSymplectic ElementsBMJ2023Green, ACACurtis, HJHiggins, RNab, LMahalingasivam, VSmith, RMMehrkar, AInglesby, PDrysdale, HDeVito, NJCroker, RRentsch, CTBhaskaran, KTazare, JZheng, BAndrews, CDBacon, SCJDavy, SDillingham, IEvans, DFisher, LHickman, GHopcroft, LEMHulme, WJMassey, JMacDonald, OMorley, JMorton, CEPark, RYWalker, AJWard, TWiedemann, MBates, CCockburn, JParry, JHester, FHarper, SDouglas, IJEvans, SJWGoldacre, BTomlinson, LAMacKenna, B<p><strong>Objective:</strong> To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England.</p> <p><strong>Design:</strong> Retrospective, descriptive cohort study, approved by NHS England.</p> <p><strong>Setting:</strong> Routine clinical data from 23.4 million people linked to data on covid-19 infection and treatment, within the OpenSAFELY-TPP database.</p> <p><strong>Participants:</strong> Outpatients with covid-19 at high risk of severe outcomes.</p> <p><strong>Interventions:</strong> Nirmatrelvir/ritonavir (paxlovid), sotrovimab, molnupiravir, casirivimab/imdevimab, or remdesivir, used in the community by covid-19 medicine delivery units.</p> <p><strong>Results:</strong> 93 870 outpatients with covid-19 were identified between 11 December 2021 and 28 April 2022 to be at high risk of severe outcomes and therefore potentially eligible for antiviral or nMAB treatment (or both). Of these patients, 19 040 (20%) received treatment (sotrovimab, 9660 (51%); molnupiravir, 4620 (24%); paxlovid, 4680 (25%); casirivimab/imdevimab, 50 (<1%); and remdesivir, 30 (<1%)). The proportion of patients treated increased from 9% (190/2220) in the first week of treatment availability to 29% (460/1600) in the latest week. The proportion treated varied by high risk group, being lowest in those with liver disease (16%; 95% confidence interval 15% to 17%); by treatment type, with sotrovimab favoured over molnupiravir and paxlovid in all but three high risk groups (Down's syndrome (35%; 30% to 39%), rare neurological conditions (45%; 43% to 47%), and immune deficiencies (48%; 47% to 50%)); by age, ranging from ≥80 years (13%; 12% to 14%) to 50-59 years (23%; 22% to 23%); by ethnic group, ranging from black (11%; 10% to 12%) to white (21%; 21% to 21%); by NHS region, ranging from 13% (12% to 14%) in Yorkshire and the Humber to 25% (24% to 25%) in the East of England); and by deprivation level, ranging from 15% (14% to 15%) in the most deprived areas to 23% (23% to 24%) in the least deprived areas. Groups that also had lower coverage included unvaccinated patients (7%; 6% to 9%), those with dementia (6%; 5% to 7%), and care home residents (6%; 6% to 7%).</p> <p><strong>Conclusions:</strong> Using the OpenSAFELY platform, we were able to identify patients with covid-19 at high risk of severe outcomes who were potentially eligible to receive treatment and assess the coverage of these new treatments among these patients. In the context of a rapid deployment of a new service, the NHS analytical code used to determine eligibility could have been over-inclusive and some of the eligibility criteria not fully captured in healthcare data. However targeted activity might be needed to resolve apparent lower treatment coverage observed among certain groups, in particular (at present): different NHS regions, ethnic groups, people aged ≥80 years, those living in socioeconomically deprived areas, and care home residents.</p> |
| spellingShingle | Green, ACA Curtis, HJ Higgins, R Nab, L Mahalingasivam, V Smith, RM Mehrkar, A Inglesby, P Drysdale, H DeVito, NJ Croker, R Rentsch, CT Bhaskaran, K Tazare, J Zheng, B Andrews, CD Bacon, SCJ Davy, S Dillingham, I Evans, D Fisher, L Hickman, G Hopcroft, LEM Hulme, WJ Massey, J MacDonald, O Morley, J Morton, CE Park, RY Walker, AJ Ward, T Wiedemann, M Bates, C Cockburn, J Parry, J Hester, F Harper, S Douglas, IJ Evans, SJW Goldacre, B Tomlinson, LA MacKenna, B Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY |
| title | Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY |
| title_full | Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY |
| title_fullStr | Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY |
| title_full_unstemmed | Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY |
| title_short | Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY |
| title_sort | trends variation and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid 19 in community settings retrospective descriptive cohort study of 23 4 million people in opensafely |
| work_keys_str_mv | AT greenaca trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT curtishj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT higginsr trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT nabl trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT mahalingasivamv trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT smithrm trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT mehrkara trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT inglesbyp trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT drysdaleh trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT devitonj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT crokerr trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT rentschct trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT bhaskarank trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT tazarej trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT zhengb trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT andrewscd trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT baconscj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT davys trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT dillinghami trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT evansd trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT fisherl trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT hickmang trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT hopcroftlem trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT hulmewj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT masseyj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT macdonaldo trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT morleyj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT mortonce trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT parkry trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT walkeraj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT wardt trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT wiedemannm trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT batesc trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT cockburnj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT parryj trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT hesterf trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT harpers trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT douglasij trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT evanssjw trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT goldacreb trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT tomlinsonla trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely AT mackennab trendsvariationandclinicalcharacteristicsofrecipientsofantiviraldrugsandneutralisingmonoclonalantibodiesforcovid19incommunitysettingsretrospectivedescriptivecohortstudyof234millionpeopleinopensafely |